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Background: Albumin and mannitol may interfere with hemo-
stasis, but their coinfluence is unclear. We aimed to determine
the effects of albumin alone and in combination with mannitol
or Ringer acetate (RAC) on hemostasis in crossover in vitro
study.
Materials and Methods: From citrated fresh whole blood with-
drawn from 10 volunteers, we prepared 2.5, 5, 10, 15, and 20
vol% dilutions of 4% albumin (Alb group). Each sample was
thereafter diluted by 15% mannitol (Alb/Man group) or RAC
(Alb/RAC group) at a ratio of 9:1. Using thromboelastometry,
FibTEM (fibrinogen ROTEM) and ExTEM (extrinsic ROTEM)
tests were performed.
Results: A 20 vol%, but not 2.5 to 15 vol% dilution of albumin
caused a prolonged clot formation time, a-angle decrease, and
maximum clot firmness (MCF) weakening compared with un-
diluted sample (P<0.05). Clot formation time prolonged more
in Alb5/Man than in Alb5 and Alb5/RAC dilution (P<0.05).
In Alb2.5/Man, Alb10/Man, and Alb15/Man, dilution a-angle
was lower than in corresponding Alb/RAC and Alb-group
dilutions (P<0.05). In ExTEM, MCF decreased similarly in
every dilution of Alb/Man and Alb/RAC compared with Alb
group (P<0.05). In FibTEM, MCF decreased more in Alb10/
Man than in Alb10/RAC dilution (P<0.05).
Conclusions: In up to 15 vol% dilutions, albumin alone did not
impair hemostasis in vitro, but in combination with mannitol or
RAC coagulation was disturbed similarly at most concen-
trations. There was some significant additional effect with
mannitol at certain concentrations. Our results indicate that
coadministration of mannitol and albumin needs further study
in vivo.
Key Words: albumin, mannitol, Ringer acetate, RAC, throm-
boelastometry, TEG, neurosurgery, neuroanesthesiology, blood
coagulation
(J Neurosurg Anesthesiol 2018;30:265–272)
Even a slightest disturbance in hemostasis can lead tocatastrophic consequences in patients undergoing
neurosurgery. Although mannitol is a solution being
infused daily to decrease intracranial pressure and im-
prove surgical conditions during craniotomy, only few
studies have evaluated the effect of mannitol on blood
coagulation.1–6 In vitro mannitol seems to interfere with
blood coagulation by reducing clot strength at 10 and 20
vol% dilutions,2 which is possibly a result from poor
fibrin clot formation.3 Data from animal studies have also
shown that mannitol impairs coagulation in vitro in a
dose-dependent manner.5 Results from 1 in vivo study,
however, indicated that the use of 5mL/kg of 20%
mannitol during elective craniotomy seems to be safe in
terms of hemostasis.6
Although crystalloids remain the first-line choice of
maintenance fluid, in severely hypovolemic patients col-
loids are still often preferred to achieve hemodynamic
stabilization faster and in a more volume-efficient way.7,8
Compared with other colloids, albumin has been thought
to have little effect on hemostasis9–15 and there are even
some data about its hypercoagulational effects at lower
hemodilution levels.10,16–18 Therefore, albumin could be
used as an alternative colloid for rapid intravascular
volume replacement and thereby maintaining adequate
tissue perfusion pressure in most neurosurgical patients.
However, because of increased mortality it should be
avoided in patients with traumatic brain injury.19,20
Both albumin and mannitol may interfere with blood
coagulation, but their coinfluence on hemostatic parameters
has so far not been demonstrated in controlled situations.
As normal hemostasis is essential in neurosurgery, it is
relevant to investigate the coeffects of these 2 solutions.
Therefore, in this crossover in vitro study we aimed to
determine whether albumin alone or in combination with
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mannitol impairs blood coagulation and if this coeffect is
enhanced at higher hemodilution levels.
MATERIALS AND METHODS
The study protocol was approved by the Ethics
Committee for Studies in Healthy Subjects and Primary
Care in the Hospital District of Helsinki and Uusimaa
(no. 57/130300/2014). Written informed consent was
obtained from every participant. We included 10 volun-
teers, who first answered the recruitment email that was
sent to mailing lists of medical students in the University
of Helsinki. All apparently healthy, nonsmoking volun-
teers were included in the study. No medication was
allowed for 5 days before blood sampling. Fasting of
6 hours was required before blood sampling. Blood sam-
pling and analyzing was performed at the Department of
Anesthesia in Helsinki University Hospital.
The test solutions were 4% albumin (Albuman,
40 g/L; Sanquin, Amsterdam, The Netherlands), 15%
mannitol (Mannitol Braun, 150mg/mL; Braun, Melsun-
gen, Germany), and RAC (Ringer acetate Baxter Viaflo;
Baxter Medical AB, Kista, Sweden) as a control solution.
The main study groups were Alb, Alb/Man, and Alb/
RAC, respectively.
Venous blood (40mL) was drawn via a 20G needle
with a minimal stasis from the antecubital vein directly
into vacuum polypropylene tubes (BD Vacutainer,
Heidelberg, Germany) containing 3.2% buffered citrate.
Immediately after sampling, blood was diluted first with
albumin-only to make 2.5, 5, 10, 15, and 20 vol% end
concentrations of the solution. Each dilution and the
undiluted blood sample was then diluted by mannitol or
RAC at a ratio of 9:1 (an additional 10 vol%
dilution, Table 1), mimicking the clinical setting, where
mannitol is normally infused 1 g/kg (500mL of 15%
mannitol for 75 kg person). Dilutions with similar end
concentrations were:
(1) Alb10, Man, and RAC (10 vol%),
(2) Alb2.5/Man and Alb2.5/RAC (12.5 vol%),
(3) Alb15, Alb5/Man, and Alb5/RAC (15 vol%),
(4) Alb20, Alb10/Man, and Alb10/RAC (20 vol%),
(5) Alb15/Man and Alb15/RAC (25 vol%),
(6) Alb20/Man and Alb20/RAC (30 vol%).
An undiluted blood sample was used as a control.
The diluted blood and undiluted control samples were
analyzed with 2 rotational thromboelastometry devices
(ROTEM-Delta; TEM International GmbH, Munich,
Germany) using tissue factor activator with (FibTEM; Tem
Innovations GmBH, Munich Germany) or without
cytochalasin D (ExTEM; Tem Innovations GmBH). Sam-
ples were analyzed within 4 hours after blood withdrawal.
Coagulation was allowed to proceed for at least 30 minutes.
Technical details and reference values21,22 of ROTEM co-
agulation tests are shown in Figure 1. Automatically mea-
sured ROTEM parameters of blood coagulation were
clotting time (CT), clot formation time (CFT), alpha-angle
(a-angle) with ExTEM, and maximum clot firmness (MCF)
with ExTEM and FibTEM. After initializing ROTEM,
hemoglobin (Hb) concentration, hematocrit (Hct) value, and
platelet count (Pc) were determined in all whole-blood
samples using a Sysmex KX-21 Haematology Analyser
(Sysmex Corporation, Japan).
Statistics
The number of volunteers was based on earlier data
regarding various in vitro colloid hemodilution stud-
ies.2,3,10 Normality of data sets was assessed with Shapiro-
Wilk tests and by examining graphically Q-Q plots. The
differences between the study groups and dilutions were
analyzed with the nonparametric repeated measures
analysis of variance test (Friedman ANOVA). For paired
comparisons and post hoc analysis, Wilcoxon signed-rank
test was used with the Bonferroni correction applied
whenever there were >2 comparisons within group.
A P<0.05 was considered statistically significant.
TABLE 1. Composition of Dilutions
Group Name Dilution Name Blood (mL) Alb (mL) Man (mL) RAC (mL)
Control 1 — — —
Alb Alb2.5 3.9 0.1 — —
Alb5 3.8 0.2 — —
Alb10 3.6 0.4 — —
Alb15 3.4 0.6 — —
Alb20 3.2 0.8 — —
Alb/Man Alb2.5/Man 0.9 of Alb2.5 — 0.1 —
Alb5/Man 0.9 of Alb5 — 0.1 —
Alb10/Man 0.9 of Alb10 — 0.1 —
Alb15/Man 0.9 of Alb15 — 0.1 —
Alb20/Man 0.9 of Alb20 — 0.1 —
Man 0.9 — 0.1 —
Alb/RAC Alb2.5/RAC 0.9 of Alb2.5 — — 0.1
Alb5/RAC 0.9 of Alb5 — — 0.1
Alb10/RAC 0.9 of Alb10 — — 0.1
Alb15/RAC 0.9 of Alb15 — — 0.1
Alb20//RAC 0.9 of Alb20 — — 0.1
RAC 0.9 — — 0.1
Alb indicates albumin; Man, mannitol; RAC, Ringer acetate.
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Results are shown as medians with 25th/75th percentiles
and percentage of undiluted value (for ROTEM param-
eters only). All statistical calculations were carried out
using the Statistical Package for Social Sciences version
21.0 (SPSS Inc., Chicago, IL) and graphs were created
with GraphPad Prism version 7.0b (GraphPad Software,
La Jolla, CA).
With hemodilutional data (Hb, Hct, and Pc), we
conducted comparisons between:
(1) Diluted and undiluted samples,
(2) Groups with similar dilutions.
With ROTEM parameters (CT, CFT, a-angle, and
MCF) we conducted comparisons between:
(1) Diluted and undiluted samples,
(2) Alb10, Man, and RAC dilutions,
(3) Main study groups, that is, dilutions with the same
level of albumin vol% dilution (eg, Alb2.5, Alb2.5/
Man, and Alb2.5/RAC, etc.), all together 5 different
comparison levels (2.5%, 5%, 10%, 15%, and 20%),
(4) The relative changes within Alb/Man group seen after
adding mannitol to Alb group dilutions.
RESULTS
Four male and 6 female volunteers aged 22 to 29
years participated in the study. Six (1 in EXTEM and 5 in
FIBTEM) of the ROTEM tracings (1.7% of all the
tracings) were technically unsuccessful and excluded from
the final analysis. The dilutional effect on Hb, Hct, and Pc
is shown in Table 2. All study solutions at all levels of
hemodilution induced a decrease in Hb, Hct, and Pc
compared with the undiluted sample (P<0.05). Hb, Hct,
and Pc did not differ, on average, between various dilu-
tions with similar end concentrations.
CT in ExTEM Analysis
CT was prolonged only in Alb15/Man dilution
(P<0.05), whereas remaining dilutions did not differ
from control sample. On an average, CT showed differ-
ence neither between study groups nor within Alb/Man
group. However, CT was longer in Man and Alb2.5/Man
than in RAC and Alb2.5/RAC dilution (P<0.05).
Normal values MCF, mm CT, sec CFT, sec α-angle, °
ExTEM® 49-71 42-74 46-148 63-81
FibTEM® 9-25
FIGURE 1. ROTEM parameters and normal values. Clotting time reflects the time from the start of the measurement until the start
of clot formation, describing the rate of fibrin formation at the beginning. Clot formation rate refers to the time from the
beginning of clot formation until a clot firmness of 20 mm has been reached, indicating how fast the clot structure is forming.
a-angle is the angle between the central-line and the tangent of the curve at the amplitude point of 2 mm, for example, clot
formation rate, denoting the rate of the formation of a solid clot. Maximum clot firmness describes the strength of the clot and
thus depends on platelet count, platelet function, and fibrinogen concentration.
TABLE 2. Hemodilution Data
Dilution Name Hb (g/L) Hct (%) Pc (10 E9/L)
Control 130 (125-133) 38 (36-40) 169 (143-199)
Alb2.5 127 (122-131)* 37 (34-39)* 141 (131-199)
Alb5 124 (119-127)* 36 (34-37)* 131 (124-183)*
Alb10 118 (113-123)* 34 (32-37)* 126 (119-181)*X
Alb15 111 (107-115)*‘ 32 (30-34)* 120 (112-162)*’
Alb20 104 (101-107)* 30 (29-32)* 119 (101-149)*
Alb2.5/Man 114 (111-119)* 33 (31-34)*y 96 (25-127)*
Alb5/Man 112 (109-115)*‘ 32 (30-34)*” 90 (26-128)*’
Alb10/Man 106 (102-111)*” 31 (29-32)* 83 (18-104)*“
Alb15/Man 99 (96-104)* 28 (27-30)* ˜ 76 (11-94)*
Alb20/Man 93 (91-99)* 27 (26-29)*# 68 (8-83)*
Man 118 (111-122)* 34 (31-36)* 95 (23-143)*
Alb2.5/RAC 115 (112-118)* 33 (32-34)* 78 (33-95)*
Alb5/RAC 112 (110-116)* 32 (31-34)* 64 (12-99)*
Alb10/RAC 104 (103-111)* 30 (29-32)* 42 (16-92)*“
Alb15/RAC 100 (98-105)* 29 (28-31)* 60 (21-71)*
Alb20/RAC 95 (91-99)* 28 (26-29)* 35 (19-63)*
RAC 117 (113-121)* 34 (32-36)* 92 (19-102)*
Medians (25th/75th percentiles) of Hb, Hct, and Pc are shown.
Alb indicates albumin; Hb, hemoglobin concentration; Hct, hematocrit value;
Man, mannitol; Pc, platelet count; RAC, Ringer acetate.
*P<0.05 compared with the undiluted sample.
‘P< 0.05 (Bonferroni correction applied) in comparison with Alb5/RAC.
XP< 0.05 (Bonferroni correction applied) in comparison with RAC.
“P< 0.05 (Bonferroni correction applied) in comparison with Alb20.
yP< 0.05 in comparison with Alb2.5/RAC.
˜P< 0.05 in comparison with Alb15/RAC.
#P< 0.05 in comparison with Alb20/RAC.
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CFT in ExTEM Analysis
In Alb group, CFT was prolonged only at 20 vol%
dilutions compared with undiluted sample (P<0.05), but
all values remained within normal range (Fig. 2). An
albumin dilution of 2.5 vol% caused CFT shortening
in comparison with undiluted sample (P<0.05). A dilu-
tion of 10 vol% with mannitol caused greater CFT delay
than RAC (P<0.05), whereas albumin had no effect at
this dilution level.
Comparing a combination of solutions, CFT was
more prolonged in Alb5/Man dilution than in Alb5/RAC
(P<0.05). In the remaining dilutions of Alb/Man group
(Alb2.5/Man, Alb10/Man, Alb15/Man, and Alb20/Man),
CFT was also prolonged compared with undiluted sample
and corresponding Alb group dilutions (Alb2.5, Alb10,
Alb15, and Alb20, respectively; P<0.05), but it was
comparable with the changes seen in similar dilutions in
Alb/RAC group (P>0.05). Within Alb/Man group, the
relative CFT prolonging compared with Alb group was
similar between different dilution levels (P>0.05).
a-Angle in ExTEM Analysis
Compared with undiluted sample, a-angle decreased





























































































































































































































































α-angle measured with ExTEM®
A
B
FIGURE 2. Box plot (minimum, 25th percentile; median, 75th percentile, maximum) values of clot formation time (A) and
a-angle (B), measured with ExTEM. P < 0.05 compared with the undiluted sample (a); P < 0.05 (Bonferroni correction applied)
between Alb and Alb/Man as well as Alb and Alb/RAC groups but not between Alb/Man and Alb/RAC groups within same level of
albumin vol% dilution (b); P < 0.05 (Bonferroni correction applied) between all groups (Alb, Alb/Man and Alb/RAC) within same
level of albumin vol% dilution or between Alb10, Man and RAC dilutions (c); P < 0.05 (Bonferroni correction applied) between Alb
and Alb/Man as well as Alb/Man and Alb/RAC groups but not between Alb and Alb/RAC groups within same level of albumin
vol% dilution (d).
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groups, but in Alb-only group at 20 vol% dilution
(P<0.05, Fig. 2). At 10 vol% dilution there were similar
differences in a-angle decrease (as the ones seen with CFT)
between Alb10, Man, and RAC dilutions—mannitol
decreased a-angle the most, RAC less (P<0.05), and
albumin had no effect.
a-angle was lower in Alb2.5/Man, Alb10/Man, and
Alb15/Man dilution than in corresponding Alb/RAC and
Alb group dilutions (P<0.05; Fig. 2). In Alb/Man
group, relative changes of a-angle caused by adding
mannitol to each albumin dilution were not more
enhanced at higher dilution levels (P>0.05).
MCF in ExTEM and FibTEM Analysis
In ExTEM analysis, albumin induced MCF weak-
ening compared with control from 10 vol% hemodilution
(P<0.05), although all values remained within the normal
range (Fig. 3). In FibTEM analysis, albumin caused
significant MCF decrease only at 20 vol% dilution
































































































































































































































































FIGURE 3. Box plot (minimum, 25th percentile; median, 75th percentile, maximum) values of maximum clot firmness (MCF),
measured with ExTEM (A) and FibTEM (B) tests. P < 0.05 compared with the undiluted sample (a); P < 0.05 (Bonferroni correction
applied) between Alb and Alb/Man as well as Alb and Alb/RAC groups but not between Alb/Man and Alb/RAC groups within
same level of albumin vol% dilution or between Alb10 and Man as well as Alb10 and RAC dilution but not between Man and RAC
dilution (b); P < 0.05 (Bonferroni correction applied) between Alb and Alb/Man groups but not between Alb and Alb/RAC nor Alb/
Man and Alb/RAC groups within same level of albumin vol% dilution (c); P < 0.05 (Bonferroni correction applied) between all
groups (Alb, Alb/Man and Alb/RAC) within same level of albumin vol% dilution (d).
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dilution of mannitol or RAC, MCF decrease measured by
ExTEM analysis was comparable between those solutions
(P>0.05), but both solutions caused greater MCF
decrease than albumin did (P<0.05). In FibTEM analysis,
there was no difference between Alb10, Man, and RAC.
In ExTEM analysis, MCF decreased more in every
dilution of Alb/Man and Alb/RAC compared with Alb
group (P<0.05), but mannitol did not decrease MCF
more than RAC did at any dilution level (P>0.05).
However, in FibTEM analysis MCF decrease was more
pronounced in Alb10/Man than in Alb10/RAC dilution
(P<0.05). In Alb/Man group, relative MCF weakening
(measured by both, ExTEM and FibTEM) compared
with Alb was similar between different dilution levels
(P>0.05).
DISCUSSION
The major findings of this in vitro study were: (i) the
combination of albumin and mannitol impaired hemo-
stasis slightly more than the combination of albumin and
RAC solution; but (ii) this effect was not enhanced at a
greater hemodilution level; (iii) hemodilution with 20
vol% of albumin, but not with 2.5 to 15 vol%, resulted in
marginal disturbance of blood coagulation; and (iv) 10
vol% hemodilution with albumin had the least and
mannitol the most negative effects on hemostasis.
Comparing 3 study solutions at 10 vol% dilution,
mannitol had the most deleterious effect on hemostasis
parameters—CFT prolonged>2-fold compared with
undiluted sample (unchanged and 1.5-fold with albumin
and RAC, respectively). a-angle decreased also with man-
nitol and RAC, but the changes were not as pronounced as
in CFT. The differences between mannitol and RAC after
10 vol% hemodilution were comparable with previous
in vitro findings of mannitol and 0.9% saline.3 However,
1 randomized prospective double blind clinical study on
elective craniotomy patients concluded that neither man-
nitol nor hypertonic saline induced coagulation impairment
measured by ROTEM and standard coagulation tests,
although there was a slight increase in CFT measured in
ExTEM and decrease in fibrinogen level (with values re-
maining in normal range). However, the authors concluded
that, although the administration of hypertonic solutions
reduced the levels of platelets and fibrinogen significantly,
because of a dilutional effect, it was not enough to reduce
MCF.6 Another clinical study reported that CFT altered
significantly from baseline after administration of mannitol
alone as well as in combination with hydroxyethyl starch
(HES) and MCF measured with FIBTEM did not change
from baseline, but differed significantly between groups.23
Nevertheless, as all ROTEM values remained within
normal range, the authors also concluded that mannitol
and HES can be safely administered in patients undergoing
craniotomy for supratentorial tumors. These were both
single-center studies, including 30 to 40 elective craniotomy
patients without preexisting coagulopathies, who received
20% mannitol 1 g/kg intraoperatively, resulting in lower
dilution than in any of the previous experimental studies.
Further clinical studies are, therefore, needed to show
whether the lower hemodilution using more concentrated
mannitol might be the key to avoid its possible hypo-
coagulational effect or does mannitol in contrary to in vitro
findings really have no impact on hemostasis in vivo.
In the current study, the combination of albumin
with mannitol compromised coagulation more than the
combination of albumin with RAC. This observation
supports the idea that detrimental effects of mannitol
on hemostasis in vitro seem to have other than pure
dilutional mechanism.2,3 This was particularly seen at
some hemodilution levels, where albumin combined with
mannitol caused greater coagulation abnormalities than
combined with RAC, as seen by longer CFT and lower
a-angle in ExTEM and weaker MCF in FibTEM. The
dilutional effect of mannitol on coagulation has also been
demonstrated in a previous study without a control
group, where mannitol seemed to disturb clotting mainly
by overall clot formation and strength but also by pure
fibrin clot firmness at 20 vol% hemodilution.3 Moreover,
comparison of the 3 study solutions’ effects in vitro also
revealed that mannitol alone caused more impairment in
hemostasis than other solutions.
Our observations on the coeffects of mannitol and
albumin as a colloid are consistent with the results of a
similar earlier in vitro study, which determined the effect
of mannitol with HES or RAC on blood coagulation.2 It
was shown that 10 vol% and 20 vol% hemodilution
in vitro with mannitol in combination with HES impaired
whole-blood coagulation more than mannitol in combi-
nation with RAC. The impairment in coagulation was
seen by delayed initiation of coagulation and fibrin
formation and decreased MCF in FibTEM, similar to the
findings of this study. The combination of mannitol and
colloid (albumin or HES) decreased clot firmness mea-
sured with ExTEM compared with undiluted samples in
both studies, but Lindroos and colleagues showed that
MCF in 20 vol% dilution of mannitol with HES was
lower than MCF in corresponding dilution with RAC,
whereas in our study the decrease was comparable after
mixing blood with albumin and mannitol or RAC (also at
20 vol% dilution). On the basis of the findings of these
2 studies, CT measured with ExTEM seemed to be
unaffected by the combination of mannitol and albumin
or HES.
Up to 15 vol% hemodilution in vitro, changes in
blood clotting following albumin administration were
minimal, as has been also previously shown.10 The
impairment in whole-blood coagulation was more clearly
seen in hemodilution of 20 vol% with albumin. However,
all median changes in thromboelastometric parameters
(MCF, CFT, and a-angle) remained within normal
reference range, that is, in standard clinical situations
these slightly hypocoagulational effects might be of minor
importance. In contrast, these minor changes may
nevertheless play an important role in a patient predis-
posed to coagulopathy, for example, trauma patients with
concomitant hemorrhagic shock. Previously it has been
shown, that albumin may also cause hypercoagulation,
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mainly by shortening CT in low to moderate hemodilu-
tions.10,16–18 In the present study, slight hemodilution
(2.5 and 5 vol%) with albumin showed a minor trend of
hypercoagulability (MCF strengthening in both ExTEM
and FibTEM, increase in a-angle and shortening of CFT
in ExTEM), but these findings were not all statistically
significant.
Our study has some limitations, though. First, we
did not assess platelet function, which might be decreased
after administration of hypertonic solutions, as has been
reported previously.4 Second, we investigated only 10
vol% dilution with mannitol, but there is registered
mannitol solutions with various concentration to be used
in clinical practice, so, the desired effect could be achieved
by different volumes and the dilutional effects of this
solution might therefore vary greatly. At last, the most
substantial limitation is that in vitro studies lack
generalizability to clinical situations. The study was
conducted under controlled conditions with whole blood
withdrawn from healthy volunteers without preexisting
coagulopathies. In vivo, the patient often does not receive
albumin alone, but together with crystalloids. Also, as
ROTEM measurements are classically performed in the
absence of endothelial cells, our in vitro findings do not
directly reflect the coagulational effects of investigated
solutions in vivo, where endothelium counteracts hemo-
stasis by providing tissue factor, thrombin inhibitors and
receptors for protein C activation. Moreover, no fluid
redistribution, buffering, or electrolyte homeostasis can
happen in vitro. Therefore, the findings of this study
cannot be extrapolated directly into clinical practice, but
only aim to create a platform for further clinical studies to
determine clear in vivo impact of combination of man-
nitol and albumin on coagulation.
Although current neurotrauma guidelines recom-
mend mannitol for trauma patients with elevated intra-
cranial pressure,24 hypertonic saline has been shown to be
at least as effective25 or even better26 than mannitol in
reducing brain swelling, and from a hemostatic point of
view hypertonic saline might be more suitable than man-
nitol in neurosurgery or neurointensive care.3 So, whenever
a possible coagulopathy is suspected during craniotomy,
the coadministration of albumin and mannitol should be
considered cautiously, especially because hypertonic saline
seems to be safer alternative to mannitol.
CONCLUSIONS
Up to 15 vol% dilution, albumin caused in vitro
marginal disturbances in ROTEM parameters. Mannitol
in combination with albumin impaired clot propagation
and firmness in vitro, but the effect was not enhanced at
higher hemodilution levels. The detected detrimental ef-
fects of mannitol on coagulation seem to be mostly a
dilutional consequence. Our observations may indicate
that the simultaneous administration of mannitol and
albumin might increase the risk of bleeding and should
therefore be studied further in clinical settings.
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Equiosmolar solutions of hypertonic saline and mannitol do not
impair blood coagulation during elective intracranial surgery.
J Neurosurg Anesthesiol. 2017;29:8–13.
7. Shaw AD, Kellum JA. The risk of AKI in patients treated with
intravenous solutions containing hydroxyethyl starch. Clin J Am Soc
Nephrol. 2013;8:497–503.
8. Perel P, Roberts I, Ker K. Colloids versus crystalloids for fluid
resuscitation in critically ill patients. Cochrane Database Syst Rev.
2013;2:CD000567.
9. Egli GA, Zollinger A, Seifert B, et al. Effect of progressive
haemodilution with hydroxyethyl starch, gelatin and albumin on
blood coagulation. Br J Anaesth. 1997;78:684–689.
10. Niemi TT, Kuitunen AH. Artificial colloids impair haemostasis. An
in vitro study using thromboelastometry coagulation analysis. Acta
Anaesthesiol Scand. 2005;49:373–378.
11. Haas T, Preinreich A, Oswald E, et al. Effects of albumin 5% and
artificial colloids on clot formation in small infants. Anaesthesia.
2007;62:1000–1007.
12. Caballo C, Escolar G, Diaz-Ricart M, et al. Impact of experimental
haemodilution on platelet function, thrombin generation and clot
firmness: effects of different coagulation factor concentrates. Blood
Transfus. 2013;11:391–399.
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